Natural History of Depression, Bipolar Disorder and Suicide Risk
Sponsor: National Institute of Mental Health (NIMH)
A observational or N/A phase clinical study on Analgesics and Anesthetics, this trial is actively recruiting participants. The trial is conducted by National Institute of Mental Health (NIMH) and has accumulated 21 data snapshots since 2024. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Study Description(click to expand)Study Description:
This proposal would collect systematic data on individuals undergoing personalized treatments for depression, bipolar disorder and suicide risk within the Experimental Therapeutics and Pathophysiology Branch (ETPB). The ETPB recruits individuals with treatment-resistant mood disorders from around the country. After research participation, they are often offered a course of standard treatment, tailored to clinical needs, for clinical stabilization and discharge back to non-NIH clinicians. This protocol would allow for clinical ratings in-person and remotely throughout clinical standard treatments, as well as neurobiological procedures at baseline and study termination to identify potential clinical and demographic predictors and biomarkers of treatment response.
Objectives:
The primary objective is to identify predictors of antidepressant treatment response.
The secondary and tertiary objectives are to identify predictors of suicide ideation response to treatment, and biomarkers of antidepressant response to treatment, respectively.
Endpoints:
Primary Endpoint: Score on the Montgomery Asberg Depression Rating Scale
Secondary Endpoint: Score on the Scale for Suicidal Ideation
Study Description:
This proposal would collect systematic data on individuals undergoing personalized treatments for depression, bipolar disorder and suicide risk within the Experimental Therapeutics and Pathophysiology Branch (ETPB). The ETPB recruits individuals with treatment-resistant mood disorders from around the country. After research participation, they are often offered a course of standard treatment, tailored to clinical needs, for clinical stabilization and discharge back to non-NIH clinicians. This protocol would allow for clinical ratings in-person and remotely throughout clinical standard treatments, as well as neurobiological procedures at baseline and study termination to identify potential clinical and demographic predictors and biomarkers of treatment response.
Objectives:
The primary objective is to identify predictors of antidepressant treatment response.
The secondary and tertiary objectives are to identify predictors of suicide ideation response to treatment, and biomarkers of antidepressant response to treatment, respectively.
Endpoints:
Primary Endpoint: Score on the Montgomery Asberg Depression Rating Scale
Secondary Endpoint: Score on the Scale for Suicidal Ideation
Status Flow
Change History
21 versions recorded-
May 4, 2026 — Present [daily]
Recruiting
-
Apr 17, 2026 — May 4, 2026 [daily]
Recruiting
-
Apr 16, 2026 — Apr 17, 2026 [daily]
Recruiting
-
Feb 2026 — Apr 2026 [monthly]
Recruiting
-
Jan 2026 — Feb 2026 [monthly]
Recruiting
▶ Show 16 earlier versions
-
Nov 2025 — Jan 2026 [monthly]
Recruiting
-
Oct 2025 — Nov 2025 [monthly]
Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting
-
Aug 2025 — Sep 2025 [monthly]
Recruiting
-
Jul 2025 — Aug 2025 [monthly]
Recruiting
-
Jun 2025 — Jul 2025 [monthly]
Recruiting
-
May 2025 — Jun 2025 [monthly]
Recruiting
-
Apr 2025 — May 2025 [monthly]
Recruiting
-
Mar 2025 — Apr 2025 [monthly]
Recruiting
-
Jan 2025 — Mar 2025 [monthly]
Recruiting
-
Dec 2024 — Jan 2025 [monthly]
Recruiting
-
Nov 2024 — Dec 2024 [monthly]
Recruiting
-
Oct 2024 — Nov 2024 [monthly]
Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Not Yet Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for mood disorders. The purpose is to understand the experience of receiving treatment for depression, bipolar disorder, and suicide risk. We also hope that this study will help us to predict which medications will improve thoughts of suicide. People 18 years or older who are receiving treatment for depression, bipolar disorder, or suicide risk may take part in this study. Participants must have also been enrolled in protocol 01-M-0254. This study will be conducted at the NIH Clinical Center in Bethesda, MD. The study typically lasts up to 12 weeks, but may last longer if a participant s treatment continues past that time. Participants will have weekly interviews and questionnaires while they are being treated for their mood disorder. Other tests are optional and include psychological testing, blood draws, sleep tests, and imaging scans. These will be done at the start and the end of research participation.
Contact Information
- National Institute of Mental Health (NIMH)
For direct contact, visit the study record on ClinicalTrials.gov .